Dermal RegenerationMSCsNCT06135519
Dermogenesis With Mesenchymal Stem Cells
A study testing Autologous Mesenchymal stem cells injection and Homogenized fat injection in people with Dermal Regeneration, run by King Edward Medical University at 1 site in Pakistan.
Trial summary
Dermogenesis With Mesenchymal Stem Cells in treating Post Acne Depressed Spots Read more about this study
- Who is it for?
- Ages Up to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Dermal Regeneration
- What is being tested?
- Autologous Mesenchymal stem cells injection and Homogenized fat injection
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 sitePakistan
- Study dates
- 23 Jul 2023to 22 Feb 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 50 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Acne spots
Who cannot join
- Active acne
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Dermogenesis With Mesenchymal Stem Cells: A Fabulous Remedy For Post Acne Depressed Spots
Dermogenesis With Mesenchymal Stem Cells in treating Post Acne Depressed Spots
Read the detailed description
management at two different stages of the course of the disease. First one at the stage of active disease which needs cleansers, antibiotics, retinoids, anti inflammatory agents and hormonal manipulation. Once active disease is over, patients report to clinician with depressed spots which are caused by localized dermal disruption and fat atrophy post inflammation or spontaneous epithelial rupture or scratching by the patient. These acne spots are hard to treat due to many reasons. Firstly, excision is difficult as size of most of them is small and they are in a large in number. Secondly, filling with and without subcision is not adequately addressing the deformity. Currently, a combination of filling with synthetic filler or fat and resurfacing by peeling, LASER or dermabrasion is in practice. In-spite of all, a treatment is still required to address post acne spots (Ice Spec Spots) adequately.
- Conditions
- Dermal Regeneration
- Being tested
- Autologous Mesenchymal stem cells injection, Homogenized fat injection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Autologous Mesenchymal stem cells injectionProcedure or surgery
Autologous Mesenchymal stem cells will be seperated from harvested fat and injected in acne scars
Homogenized fat injectionProcedure or surgery
Autologous fat will be harvested, homogenized and injected.
| Study group | Role | What they receive |
|---|---|---|
| Mesenchymal stem cells | Experimental | Mesenchymal Stem Cells taken from adipose tissue will be used Receives: Procedure: Autologous Mesenchymal stem cells injection |
| Homogenized fat | Experimental | Adipose tissue will be harvested and used Receives: Procedure: Homogenized fat injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dermal thickness
on microscopy of biopsy section
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2023
- Study start23 Jul 2023
- Primary completion22 Feb 2024
- Study completion22 Feb 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Dermal RegenerationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Group A with MSCs Group B with Fat
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- King Edward Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Afzaal Bajwa, King Edward Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06135519
- Sponsor's protocol ID
- kemu/23/2
- Acronym
- MSCs
- Status last verified
- Mar 2024
- First submitted
- 11 Nov 2023
- Last updated
- 7 Mar 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Cumulative ananlysis
Publications
Bashir A, Choudhery MS, Afzaal S, Ali S, Afzaal S. Adipose Tissue-Derived Stem Cells Enhance Dermogenesis of Post-Acne Depressed Spots. J Cosmet Dermatol. 2025 Oct;24(10):e70399. doi: 10.1111/jocd.70399.
PubMed 41078325
Study at a glance
From the registry record, last updated by the sponsor on 7 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dermogenesis With Mesenchymal Stem Cells: A Fabulous Remedy For Post Acne Depressed Spots
- ClinicalTrials.gov ID
- NCT06135519
- Acronym / sponsor ID
- MSCs / kemu/23/2
- Conditions
- Dermal Regeneration
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- King Edward Medical UniversityUniversity, hospital or other
- Study start
- 23 Jul 2023 (actual)
- Primary completion
- 22 Feb 2024 (actual)
- Study completion
- 22 Feb 2024 (actual)
- First posted
- 18 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Dermogenesis With Mesenchymal Stem Cells in treating Post Acne Depressed Spots
Detailed description
management at two different stages of the course of the disease. First one at the stage of active disease which needs cleansers, antibiotics, retinoids, anti inflammatory agents and hormonal manipulation. Once active disease is over, patients report to clinician with depressed spots which are caused by localized dermal disruption and fat atrophy post inflammation or spontaneous epithelial rupture or scratching by the patient. These acne spots are hard to treat due to many reasons. Firstly, excision is difficult as size of most of them is small and they are in a large in number. Secondly, filling with and without subcision is not adequately addressing the deformity. Currently, a combination of filling with synthetic filler or fat and resurfacing by peeling, LASER or dermabrasion is in practice. In-spite of all, a treatment is still required to address post acne spots (Ice Spec Spots) adequately.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Group A with MSCs Group B with Fat
| Arm | Type | Receives |
|---|---|---|
| Mesenchymal stem cells | Experimental | Procedure: Autologous Mesenchymal stem cells injectionMesenchymal Stem Cells taken from adipose tissue will be used |
| Homogenized fat | Experimental | Procedure: Homogenized fat injectionAdipose tissue will be harvested and used |
Who may qualify
- Ages
- Up to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (1 listed)
- Acne spots
Key exclusion criteria (1 listed)
- Active acne
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Autologous Mesenchymal stem cells injectionAutologous Mesenchymal stem cells will be seperated from harvested fat and injected in acne scars | Procedure or surgery | Mesenchymal stem cells |
| Homogenized fat injectionAutologous fat will be harvested, homogenized and injected. | Procedure or surgery | Homogenized fat |
Primary outcome
Dermal thickness
Time frame: 3 months
on microscopy of biopsy section
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Mar 2024.
- Derived from this study: PubMed 41078325Bashir A, Choudhery MS, Afzaal S, Ali S, Afzaal S. Adipose Tissue-Derived Stem Cells Enhance Dermogenesis of Post-Acne Depressed Spots. J Cosmet Dermatol. 2025 Oct;24(10):e70399. doi: 10.1111/jocd.70399.
- Individual participant dataSharing planned: No. Cumulative ananlysis
Related trials for Dermal Regeneration
Recruiting
Morphological Characteristics of Mandibular Molar Furcation Involvement and Efficacy of Regenerative Surgical Treatment
Periodontitis, Periodontitis (Stage 3)
Recruiting
Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
Diabetic Foot Ulcers (DFUs), Diabetic Foot
Recruiting
Implant Phenotype Modification Via GBR and ADM
Horizontal Ridge Deficiency
RecruitingPhase 1/2
Study of EPI-001 in Patients With Androgenetic Alopecia
Androgenetic Alopecia
Not yet recruitingPhase 1
LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults
Venous Leg Ulcer, Chronic Non-Healing Cutaneous Wounds
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Autologous Mesenchymal stem cells injection and Homogenized fat injection in people with Dermal Regeneration, run by King Edward Medical University at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dermal thickness (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06135519, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2024.